A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.

Heng MeiXiaofan LiuYan LiHu ZhouYing FengGuangxun GaoPeng ChengRuibin HuangLinhua YangJianda HuMing HouYazhou YaoLi LiuYi WangDepei WuLiansheng ZhangChangcheng ZhengXuliang ShenQi HuJing LiuJie JinJianmin LuoYun ZengSujun GaoXiaohui ZhangXin ZhouQingzhi ShiRuixiang XiaXiaobao XieZhongxing JiangLi GaoYuansong BaiYan LiJunye XiongRunzi LiJianjun ZouTing NiuRenchi YangHan Yan

Published in: Journal of hematology & oncology (2021)

In ITP patients, hetrombopag is efficacious and well tolerated with a manageable safety profile. Trial registration Clinical trials.gov NCT03222843 , registered July 19, 2017, retrospectively registered.

Keyphrases

phase iii
clinical trial
double blind
open label
phase ii
placebo controlled
end stage renal disease
newly diagnosed
study protocol
ejection fraction
prognostic factors
peritoneal dialysis
patient reported outcomes
randomized controlled trial